InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,304.80
(
0.47%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.42
(
0.00%
)
Bitcoin
61,599.75
(
-0.02%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

BTH

Send PM Follow Ignore
Followers 16
Posts 4145
Boards Moderated 1
Alias Born 06/11/2010

BTH

Re: None

Wednesday, 06/16/2010 7:49:46 PM

Wednesday, June 16, 2010 7:49:46 PM

Post# of 80490
Good data is by no means a "free pass" to success

Take a look at Curis (CRIS) today. They have had many positive indications with GDC-449 (Hedgehog inhibitor). However, when it came to a RANDOMIZED trial, the drug flunked the text, big-time. CRIS was down 50% today (and could very well happen with ARIA - I suggest PUTS against your positions FWIW)

Word to the wise to those here who claim Ridaforolimus is a sure thing because it had good data in a Phase 2 *UN-RANDOMIZED* trial.

All bets are off when you blind and randomize.

Which is why SUCCEED trial is nothing more than a 50/50 gamble.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up